Advertisement


Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy

2023 ASCO Annual Meeting

Advertisement

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses waveLINE-007, a two-part study now recruiting in more than 20 locations, to determine the safety and recommended phase II dose of the antibody-drug conjugate zilovertamab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). Efficacy of this regimen will be investigated in the second half of the study (Abstract TPS7589).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Muhit Özcan: Diffuse large B-cell lymphoma is typically treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, a regimen known as R-CHOP, but novel therapies are needed. A recent phase III study showed that replacing vincristine in R-CHOP with the antibody-drug conjugate polatuzumab vedotin was a viable approach in diffuse large B-cell lymphoma. ROR1 is an onco-fetal transmembrane protein that's expressed in a number of hematological malignancies, including diffuse large B-cell lymphomas. Zilovertamab vedotin is an antibody-drug conjugate comprising an anti-ROR1 antibody plus a cleavable linker, and the antimicrotubule cytotoxin monomethyl auristatin E, that has shown promising efficacy and manageable safety in patients with relapse or refractory hematological malignancies. The single-arm, open-label, phase II waveLINE-007 study has been designed to investigate zilovertamab vedotin in combination with R-CHP in patients with previously untreated diffuse like B cell lymphomas. Part one is being conducted to determine the safety and tolerability and recommended phase II dose of zilovertamab vedotin plus R-CHOP. Part two will be conducted to investigate the efficacy of zilovertamab vedotin plus R-CHP at the recommended phase II dose. The primary objectives of waveLINE-007 are to evaluate complete response rate based on Lugano criteria and to evaluate the safety and tolerability of zilovertamab vedotin plus R-CHP. Secondary objectives include evaluating objective response rate and the duration of response per Lugano criteria. Progression-free survival, overall survival, and the pharmacokinetics of zilovertamab vedotin plus R-CHP are exploratory. In part one, which is the dose escalation and confirmation part of the study, approximately 45 patients will receive treatment with zilovertamab vedotin plus R-CHP. The starting dose of zilovertamab vedotin is 1.75 milligram per kilogram plus R-CHP administered intravenously every 3 weeks for six cycles. Dose escalation will be based on the modified toxicity probability interval design up to a minimum of 2.5 milligram per kilogram, with the target dose limiting toxicity rate of 30%. In part one, which is the dose escalation and confirmation part of the study, approximately 45 patients with receive treatment with zilovertamab vedotin plus R-CHP. The starting dose of zilovertamab vedotin is 1.75 milligram per kilogram plus R-CHP administered intravenously every 3 weeks for six cycles. Dose escalation will be based on the modified toxicity probability interval design up to a maximum of 2.5 milligram per kilogram, with a target dose limiting toxicity rate of 30%. In the event of dose-limiting toxicities at the starting dose, the dose can also be deescalated to 1.5 milligram per kilogram. In part two, approximately 30 patients with received zilovertamab vedotin at the recommended phase II dose plus R-CHP intravenously every 3 weeks for six cycles or up to eight cycles for patients with high-risk disease. Eligible patients must be 18 years or older, have histologically confirmed diffuse large B cell lymphoma per WHO criteria, have PET-positive disease, have an ECOG performance status 0 or 1, and have an adequate organ function. Patients must not have received prior treatments for diffuse large B cell lymphoma patients with a history of transformation of indolent disease at diagnosis of primary mediastinal B-cell lymphoma, ongoing peripheral neuropathy of grade 2 or higher, or active central nervous system lymphoma will be excluded. Recruitment for waveLINE-007 is currently ongoing in Canada, Israel, Italy, Poland, Korea, Spain, and Turkey. Results from the waveLINE-007 study will provide insight into the efficacy and safety of zilovertamab vedotin plus R-CHP in patients with previously untreated diffuse large B-cell lymphomas.

Related Videos

Skin Cancer
Immunotherapy

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab

Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses phase I/II results on the efficacy of nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma. The study found that, for this rare and aggressive skin cancer, nivolumab showed clinical activity in advanced disease. However, these results from CheckMate 358 do not suggest an additional benefit with ipilimumab added to nivolumab (Abstract 9506).

 

Lymphoma

Manali K. Kamdar, MD, on Primary Refractory and Early Relapsing DLBCL: Therapeutic Options

Manali K. Kamdar, MD, of University of Colorado Hospital, discusses the treatment landscape for the 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) whose disease will relapse. Patients who experience relapse within 1 year of chemoimmunotherapy have poor outcomes with autotransplantation, but chimeric antigen receptor T-cell therapy has shown efficacy and manageable toxicity.

Skin Cancer
Immunotherapy

Allison Betof Warner, MD, PhD, and Adnan Khattak, PhD, MBBS, on High-Risk Resected Melanoma: Survival Results With mRNA-4157 and Pembrolizumab in KEYNOTE-942

Allison Betof Warner, MD, PhD, of Stanford University Medical Center, and Adnan Khattak, MBBS, FRACP, PhD, of Australia’s Hollywood Private Hospital & Edith Cowan University, discuss the use of the mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma, which prolonged distant metastasis–free survival compared with pembrolizumab alone. These results provide further evidence that a personalized neoantigen approach is potentially beneficial (Abstract LBA9503).

Bladder Cancer
Immunotherapy

Shilpa Gupta, MD, on Urothelial Carcinoma: Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab

Shilpa Gupta, MD, of Cleveland Clinic, discusses the results from the EV-103 study and the unmet need for effective first-line therapies in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. After nearly 4 years of follow-up, the trial findings showed that enfortumab vedotin-ejfv plus pembrolizumab continues to demonstrate promising survival trends with rapid and durable responses in this population (Abstract 4505).

Lung Cancer

Rami Manochakian, MD, on NSCLC: Commentary on the ADAURA Trial of Osimertinib

Rami Manochakian, MD, of Mayo Clinic Florida, offers his perspective on the new phase III findings on osimertinib, a third-generation, central nervous system EGFR tyrosine kinase inhibitor, which demonstrated an unprecedented overall survival benefit for patients with EGFR-mutated, stage IB–IIIA non–small cell lung cancer (NSCLC) after complete tumor resection, with or without adjuvant chemotherapy (Abstract LBA3).

Advertisement

Advertisement




Advertisement